Marsden Eye Specialists follow all COVID19 measures outlined by NSW Health. We aim to provide the highest standard of professional care. Click here to read more.
Home › About › Research Centre

Research Centre

Summary of clinical trials at Marsden eye research centre

At Marsden eye specialists we value the importance of evidence based research in probing for new treatments to various eye conditions. We have been involved in numerous international and local clinical trials in areas of Age-related macular degeneration (AMD), Diabetic macular edema (DME), Retinal vein occlusions (RVO) and Glaucoma. Patients enrolled in these trials have access to new advanced treatment that are in the final stages of development prior to approval and release. Our clinical research team comprises of Opthalmologists, Orthoptists and Nurses.

Our Research Team

Dr Jennifer Arnold – Head of Research, Principal Investigator and Sub Investigator (AMD, DME, BRVO, CRVO trials)

Dr Ashish Agar – Principal Investigator (Glaucoma trials)

Dr Terence Tan – Principal Investigator and Sub Investigator (AMD, DME, BRVO, CRVO trials)

Dr Helene Cass – Principal Investigator and Sub Investigator (AMD, DME, BRVO, CRVO trials)

Dr Samuel Dance - Sub Investigator (AMD, DME, BRVO, CRVO trials)

Trish Forsyth – Clinical trials coordinator

Ivy Chow, Mitchell Bagley, Pelin Cildiroglu, Narendran Kumaraselvam, Lara Greig – Orthoptists

Anh Nguyen – Clinical trials assistant

Julie Bolan, Don Tolentino – Nurses

Current recruiting clinical trials

Dry AMD

  • Honu – A Multicenter, Prospective, Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

Wet AMD

  • Coast – A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

Current Active Clinical Trials

DME

  • Ripples – Evaluation of Safety and Efficacy of the IBE-814 Intravitreal Implant in Patients with Diabetic Macular Oedema and Macular Oedema due to Retinal Vein Occlusion
  • Condor- A 96-week, two-arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopath

Geographic Atrophy Trials

  • Ionis – A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
  • Alexion – A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
  • Gale - A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Retinal Vein Occlusions

  • Ripples – Evaluation of Safety and Efficacy of the IBE-814 Intravitreal Implant in Patients with Diabetic Macular Oedema and Macular Oedema due to Retinal Vein Occlusion

Wet AMD

  • Pulsar - Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
  • MyLight - A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration

Please contact Clinical Trials Co-ordinator Trish Forsyth on  or email enquiry@marsdeneye.com if you would like further information.